Generic Name:
onasemnogene abeparvovec
Project Status:
Complete
Therapeutic Area:
Spinal muscular atrophy (SMA), pediatrics
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Zolgensma
Project Line:
Reimbursement Review
Project Number:
SG0649-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
Zolgensma is an adeno-associated virus (AVV) vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene
Submission Type:
Initial
Fee Schedule:
Schedule E
Indications:
​Zolgensma is an adeno-associated virus (AVV) vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
Date NOC Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.